Recently, The Cancer Genome Atlas project confirmed that about 45 % of GBM tumors harbor either focal amplification, mutation, or both of the EGFR gene[13], confirming that EGFR is a critical mediator of GBM pathogenesis and therefore represents a potentially important therapeutic target. Here, EGFR is linked to glioblastoma.